Julie R Brahmer

12PUBLICATIONS

165CO-AUTHORS

Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRegenerative medicine (incl. stem cells)Oncology and carcinogenesis not elsewhere classified

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (12)

Sort by Publication Date:

|Jun 26, 2026

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Apr 19, 2026

Serial Plasma Comprehensive Genomic Profiling Captures Therapy Resistance and Guides Management of Non-Small Cell Lung Cancer.

|Sep 15, 2025

Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Jan 08, 2025

Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.

Mark M Awad, Patrick M Forde, Nicolas Girard

|Nov 15, 2024

Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint Blockade.

Samuel Rosner, Sydney Connor, Khaled Sanber

|Feb 26, 2024

Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC.

Mari Nakazawa, Guilherme Harada, Paola Ghanem

Pageof 2

Frequent Collaborators

Patrick M Forde

Valsamo Anagnostou

Kristen A Marrone

Samuel Rosner

Benjamin Levy

Susan C Scott

Josephine Feliciano

Kellie N Smith

Joseph C Murray

Christine L Hann

Frequent Collaborators

Patrick M Forde

Valsamo Anagnostou

Kristen A Marrone

Samuel Rosner